

# TARC-002 EVALUATION OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) IN PATIENTS WITH LYMPHADENOPATHY , FEVER OR NON-HODGKIN LYMPHOMA

Published: 10-04-2017

Last updated: 15-04-2024

To evaluate TARC in patients with fever, lymphadenopathy or non-Hodgkin lymphoma

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Other condition
<b>Study type</b>	Observational invasive

## Summary

### ID

NL-OMON45645

### Source

ToetsingOnline

### Brief title

TARC IN PATIENTS WITH LYMPHADENOPATH, FEVER OR NON-HODGKIN LYMPHOMA

### Condition

- Other condition
- Lymphomas Hodgkin's disease
- Ancillary infectious topics

### Synonym

Fever, lymph node enlargment, lymphoma

### Health condition

andere ziekten gepaard met lymfeklier vergroting

## Research involving

Human

## Sponsors and support

**Primary sponsor:** Universitair Medisch Centrum Groningen

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** Diagnostic, Hodgkin, Lymphadenopathy, TARC

## Outcome measures

### Primary outcome

Mean TARC levels (pg/mL) in correlation with final diagnosis.

### Secondary outcome

Not applicable.

## Study description

### Background summary

Thymus and activation regulated chemokine (TARC) is elevated in about 90% of patients with classical Hodgkin lymphoma (cHL). TARC levels correspond with tumour volume and are used as a biomarker for treatment response. It is unclear whether TARC levels are also influenced by inflammatory states or can be elevated in patients with lymphadenopathy or other subtypes of lymphoma.

### Study objective

To evaluate TARC in patients with fever, lymphadenopathy or non-Hodgkin lymphoma

### Study design

This is a prospective study to determine TARC levels in patients with lymph node enlargement of unknown origin, fever and in patients who are already diagnosed with non-Hodgkin lymphoma subtypes. TARC levels will be matched with final diagnosis and compared with TARC levels of healthy controls and patients

with Hodgkin lymphoma, which have already been collected in previous studies.

### **Study burden and risks**

Since this study only involves a single blood draw during routine diagnostic procedures there is no additional safety risk.

## **Contacts**

### **Public**

Universitair Medisch Centrum Groningen

Hanzeplein 1  
Groningen 9700 RB  
NL

### **Scientific**

Universitair Medisch Centrum Groningen

Hanzeplein 1  
Groningen 9700 RB  
NL

## **Trial sites**

### **Listed location countries**

Netherlands

## **Eligibility criteria**

### **Age**

Adults (18-64 years)

Elderly (65 years and older)

### **Inclusion criteria**

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

- Age \* 18 years;

3 - TARC-002 EVALUATION OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) IN PATIE ...  
25-05-2025

- Ability to give written informed consent;

And one of the following:

- (1) Lymph node enlargement of unknown cause for which a diagnostic fine needle aspiration will be performed or
- (2) Presenting with fever at the emergency department or
- (3) Presenting with newly diagnosed or relapsed nodular lymphocyte predominant or non-Hodgkin lymphoma.

## Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study (applicable to all subgroups):

- Ineligibility to give written informed consent;
- Patients with active atopic disease or hepatic failure;
- Patients already diagnosed with Hodgkin lymphoma

## Study design

### Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 17-05-2017

Enrollment: 300

Type: Actual

## Ethics review

Approved WMO

Date: 10-04-2017

Application type: First submission

4 - TARC-002 EVALUATION OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) IN PATIE ...  
25-05-2025

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
CCMO	NL59373.042.16
Other	nummer volgt